Carcinogenesis Advance Access originally published online on June 13, 2006
Carcinogenesis 2006 27(11):2235-2242; doi:10.1093/carcin/bgl089
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common variants in mismatch repair genes and risk of invasive ovarian cancer
1 CR-UK Department of Oncology, University of Cambridge Strangeways Research Laboratory, Cambridge, UK
2 Translational Research Laboratory, Department of Gynaecological Oncology, University College London UK
3 Department of Cancer Genetics, Roswell Park Cancer Institute Buffalo, NY, USA
4 Department of Viruses, Hormones, and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society Copenhagen, Denmark
5 Gynaecologic Clinic, The Juliane Marie Centre, Rigshospitalet, University of Copenhagen Denmark
6 Department of Health Research and Policy, Stanford University School of Medicine Stanford, CA, USA
7 CR-UK Genetic Epidemiology Unit, University of Cambridge, Strangeways Research Laboratory Cambridge, UK
*To whom correspondence should be addressed. Tel: +0044 1223 740161, Fax: +0044 1223 740147; Email: honglin{at}srl.cam.ac.uk
Mismatch repair (MMR) is important for repairing of nucleotide mismatches during DNA replication. Germline mutations in MMR genes are associated with hereditary non-polyposis colorectal cancer (HNPCC). Ovarian cancer occurs as part of the HNPCC phenotype, and so common variants in MMR genes are candidates for ovarian cancer susceptibility. We performed a large multicentre case–control study to investigate associations of common variations in MMR genes and ovarian cancer using a single nucleotide polymorphism (SNP) tagging approach. A total of 2570 controls and 1531 cases from three separate studies were genotyped for 44 tagging SNPs (stSNP) in seven MMR genes (MLH1, MLH3, MSH2, MSH3, MSH6, PMS1 and PMS2). Genotype frequencies were marginally different between cases and controls for PMS2 rs7797466 (P2df = 0.046) with a 1.17-fold (95% CI 1.03–1.33) increase in risk for each ‘a’ allele carried (P-trend = 0.013). Haplotype analysis of PMS2 also showed significant differences in frequencies between cases and controls (P7df = 0.005), with one haplotype accounting for most of the effect. There was also marginal evidence for a recessive protective effect with common homozygote as the baseline comparator for two SNPs—MSH6 rs3136245 (OR 0.67; 95% CI 0.46–0.98) and MSH3 rs6151662 (OR 0.28; 95% CI 0.08–0.91)—but the comparisons of genotype frequencies for these variants were not significant (P = 0.10 and 0.054). In conclusion, it is unlikely that common variants in MLH1, MLH3, PMS1, MSH2, MSH3 and MSH6 contribute significantly to ovarian cancer susceptibility. The observed association of PMS2 rs7797466 with ovarian cancer warrants confirmation in an independent study.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Beesley, S. J. Jordan, A. B. Spurdle, H. Song, S. J. Ramus, S. K. Kjaer, E. Hogdall, R. A. DiCioccio, V. McGuire, A. S. Whittemore, et al. Association Between Single-Nucleotide Polymorphisms in Hormone Metabolism and DNA Repair Genes and Epithelial Ovarian Cancer: Results from Two Australian Studies and an Additional Validation Set Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2557 - 2565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Gayther, H. Song, S. J. Ramus, S. K. Kjaer, A. S. Whittemore, L. Quaye, J. Tyrer, D. Shadforth, E. Hogdall, C. Hogdall, et al. Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer Cancer Res., April 1, 2007; 67(7): 3027 - 3035. [Abstract] [Full Text] [PDF]
|
|